Wyden Press Conference Remarks on Investigation into Gilead’s Pricing of Hepatitis Drug Sovaldi
WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., delivered the following remarks at a press conference with Senator Chuck Grassley, R-Iowa, a senior member of the committee, following the release of their bipartisan investigation into the pricing of Gilead Sciences blockbuster Hepatitis C drug, Sovaldi. Video of the press conference can be found […]
Wyden-Grassley Sovaldi Investigation Finds Revenue-Driven Pricing Strategy Behind $84,000 Hepatitis Drug
18-Month Investigation Reveals a Pricing and Marketing Strategy Designed to Maximize Revenue with Little Concern for Access or Affordability Report Includes Landmark Release of Medicaid Data: In 2014, More than $1 Billion Spent by Medicaid Programs on Sovaldi Treated Less than 2.4 Percent of Enrolled Patients with Hepatitis C Medicare Spent More on Gilead Hepatitis […]
Wyden Statement on Pfizer-Allergan Merger
Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today issued the following statement on the proposed merger between pharmaceutical companies Pfizer and Allergan: “The Treasury Department has made it very clear that its efforts to halt the inversion virus and stop the further erosion of our tax base can only go so far. The only […]
Wyden Statement Regarding New Treasury Guidance on Inversions
WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today issued the following statement: “We welcome efforts from Treasury to curb overseas tax inversions. Ultimately it’s up to Congress to deliver tax policy that better equips companies to compete and succeed by staying in the U.S. And the only way to get that done, and […]
Wyden Requests Update on 1332 Waiver Implementation from HHS
WASHINGTON – Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today sent a letter to Department of Health and Human Services (HHS) Secretary Sylvia Mathews Burwell to inquire about the Department’s preparations for when states are allowed to apply for the waivers in 2017. “State Innovation Waivers allow pioneering states to take the reins and come […]
Wyden Hearing Statement on Physician-Owned Distributorships
When you walk into a doctor’s office, you’re putting an extraordinary level of trust — and maybe even your life — in your physician’s hands. Today the Finance Committee will hear about one type of business called a physician-owned distributorship that in some cases might violate that trust with dangerous and life-threatening consequences. […]
Wyden to DOJ, FTC: Reported Beer Merger Must Not Crowd Out Craft Brewers, Raise Beer Prices and Hurt Consumers
WASHINGTON –Following reports of merger discussions between beer makers Anheuser-Busch InBev and SABMiller, Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today urged the Federal Trade Commission and Department of Justice to weigh in any future review process how a deal would affect craft brewers, consumers and distributors in Oregon and across the country. Recent […]
Wyden Statement on Release of Trans-Pacific Partnership Text
WASHINGTON –Senate Finance Committee Ranking Member Ron Wyden, D-Ore., promised to dig into the details of the Trans-Pacific Partnership agreement between the United States and 11 Asian Pacific nations, which was released today. “I look forward to digging into the details of what was released today. In the days and weeks ahead I will be […]
Wyden Statement on CMS Decision on Biosimilar Drug Payment Rule
Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today issued a statement following an announcement from the Centers for Medicare & Medicaid Services (CMS) regarding how it will pay for biosimilar biological products: “Today’s decision will foster a competitive market for biosimilar drugs that focuses on value, which is what Americans expect. I applaud CMS […]
Wyden Statement on Increased Congressional Staff Access to Trade Documents
WASHINGTON – Finance Committee Ranking Member Ron Wyden, D-Ore., praised increased access to trade documents for Congressional staff that went into effect this week under new consultation and engagement guidelines released by the Office of the U.S. Trade Representative. Wyden successfully fought for the new guidelines, including increased staff access to trade documents, as part […]